Hypertension, the changing pattern of drug usage

Cardiovascular Journal of Africa

Volumn 20, Issue 1, 2009, Pages 52-56

  Opie, Lionel H ^a  

^a Faculty of Health Sciences   (South Africa)

Author keywords

[No Author keywords available]

Indexed keywords

ALISKIREN; AMLODIPINE; ATENOLOL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CAPTOPRIL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; NIFEDIPINE; PERINDOPRIL; PLACEBO; RESERPINE; TEPROTIDE;

AGEUSIA; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; DRUG COST; DRUG PREFERENCE; DRUG SAFETY; DRUG USE; HEART FAILURE; HUMAN; HYPERTENSION; HYPOKALEMIA; ISCHEMIC HEART DISEASE; KIDNEY INJURY; NEUTROPENIA; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; RENOVASCULAR HYPERTENSION; REVIEW; SKIN MANIFESTATION; STROKE; UNSPECIFIED SIDE EFFECT;

ADRENERGIC BETA-ANTAGONISTS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANTIHYPERTENSIVE AGENTS; CALCIUM CHANNEL BLOCKERS; DIURETICS; EVIDENCE-BASED MEDICINE; GUIDELINE ADHERENCE; HUMANS; HYPERTENSION; PHYSICIAN'S PRACTICE PATTERNS; PRACTICE GUIDELINES AS TOPIC; SOCIETIES, MEDICAL; SOUTH AFRICA; TIME FACTORS;

EID: 64649102496     PISSN: 19951892     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (25)

1. Cranston W, Juel-Jensen B, Semmence A, Handfield Jones R, Forbes J, Mutch L. Effects of oral diuretics on raised arterial pressure. Lancet 1963; 2: 966-969.
2. Pritchard B. Use of propanolol in the treatment of hypertension. Br Med J 1964; 2:725.
3. MRC Working Party. Medical Research Council trial of treatment of hypertension in older adults: principal results. Br Med J 1992; 304: 405-412.
4. Messerli FH, Grossman E, Goldbourt U. Are beta-blockers efficacious as first-line therapy for hypertension in the elderly? A systematic review. JAm Med Assoc 1998; 279: 1903-1907.
5. Opie LH, Schall R. Old antihypertensives and new diabetes. J Hypertens 2004; 22: 1453-1458.
6. Lindholm LH, Carlberg B, Samuelsson O. Should beta blockers remain first choice in the treatment of primary hypertension? A meta-analysis. Lancet 2005; 366: 1545-1553.
7. Williams B. Recent hypertension trials: implications and controversies. JAm Coll Cardiol 2005; 45: 813-827.
8. Bradley HA, Wiysonge CS, Volmink JA, Mayosi BM, Opie LH. How strong is the evidence for use of beta-blockers as first-line therapy for hypertension? Systematic review and meta-analysis. J Hypertens 2006; 24:2131-2141.
9. Wiysonge CS, Volmink J, Opie LH. Beta-blockers and the treatment of hypertension: it is time to move on. Cardiiovasc J Afr 2007; 18: 351-352.
10. Wiysonge CS, Bradley H, Mayosi BM, et al. Beta-blockers for hypertension. Cochrane Database Syst Rev 2007: CD002003.
11. Opie LH. Beta-blockade should not be among several choices for initial therapy of hypertension. J Hypertens 2008; 26: 161-163.
12. Mancia G, Zanchetti A. Choice of antihypertensive drugs in the European Society of Hypertension-European Society of Cardiology guidelines: specific indications rather than ranking for general usage. J Hypertens 2008; 26: 164-168.
13. Bangalore S, Sawhney S, Messerli FH. Relation of Beta-Blocker- Induced Heart Rate Lowering and Cardioprotection in Hypertension. J Am Coll Cardiol 2008; 52: 1482-1489.
14. Kaplan NM. Beta-Blockers in Hypertension Adding Insult to Injury. J Am Coll Cardiol 2008; 52: 1490-1491.
15. Tigerstedt R, Bergman PG. Niere und Kreislauf. Skand Arch Physiol 1898; 8: 223-271.
16. Duhme DW, Sancho J, Athanasoulis C, Haber E, Koch-Weser J. Letter: Hypotension during administration of angiotensin converting enzyme inhibitor SQ 20,881. Lancet 1974; 1: 408.
17. Bakhle YS. Conversion of angiotensin I to angiotensin II by cell-free extracts of dog lung. Nature 1968; 220: 919-921.
18. Furberg CD, Psaty BM, Meyer JV. Nifedipine. Dose-related increase in mortality in patients with coronary heart disease. Circulation 1995; 92: 1326-1331.
19. Opie LH, Messerli FH. Nifedipine and mortality. Grave defects in the dossier. Circulation 1995; 92: 1068-1073.
20. Opie LH, Yusuf S, Kübler W Current status of safety and efficacy of calcium channel blockers in cardiovascular diseases. A critical analysis based on 100 studies. Prog Cardiovasc Dis 2000; 43: 171-196.
21. ALLHAT Collaborative Research Group. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAm Med Assoc 2002; 288: 2981-2997.
22. Dahlöf B, Sever PS, Poulter NR, et al. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial. Lancet 2005; 366: 895-906.
23. Opie LH, Seedat YK. Hypertension in sub-Saharan African populations. Circulation 2005; 112: 3562-3568.
24. Gaziano TA, Young CR, Fitzmaurice G, Atwood S, Gaziano JM. Laboratory-based versus non-laboratory-based method for assessment of cardiovascular disease risk: the NHANES I Follow-up Study cohort. Lancet 2008; 371: 923-931.
25. Opie LH, Gersh BJ (eds). Drugs for the Heart, 7th edn. Philadelphia: Elsevier, 2008.